Get the Stockscreener App
8.01
1.60%
-0.13
After Hours:
8.06
0.05
+0.62%
Ocular Therapeutix Inc stock is traded at $8.01, with a volume of 2.18M.
It is down -1.60% in the last 24 hours and down -2.44% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$8.14
Open:
$8.08
24h Volume:
2.18M
Relative Volume:
1.28
Market Cap:
$1.28B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-5.9333
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
+9.73%
1M Performance:
-2.44%
6M Performance:
-19.01%
1Y Performance:
+38.10%
1-Day Range:
$7.71
$8.15
1-Week Range:
$6.86
$8.2099
52-Week Range:
$4.79
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.01 | 1.16B | 61.10M | -138.36M | -90.59M | -1.35 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Ocular Therapeutix (OCUL) Maintains "Buy" Rating with $15 Price Target | OCUL Stock News - GuruFocus
Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE - Defense World
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews - Benzinga
Ocular Therapeutix (OCUL) Advances with Axpaxli Trial Completion - GuruFocus
Ocular gains as Wet AMD trial for lead asset reaches enrollment target - MSN
Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry? - simplywall.st
Sector Update: Health Care - marketscreener.com
Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion - marketscreener.com
Ocular stock gains after wet AMD trial update (OCUL:NASDAQ) - Seeking Alpha
Ocular Therapeutix chief scientific officer sells $21,712 in stock - Investing.com Australia
Ocular Therapeutix (OCUL) Concludes Enrollment for Key Retinal Trial | OCUL Stock News - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for - GlobeNewswire
Record-Breaking 555-Patient Trial Could Transform AMD Treatment with 12-Month Dosing Innovation - Stock Titan
Ocular Therapeutix chief scientific officer sells $21,712 in stock By Investing.com - Investing.com Canada
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $755,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
D. E. Shaw & Co. Inc. Takes $268,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix at Stifel 2025 Forum: Eyeing a Disruptive Future By Investing.com - Investing.com Canada
(OCUL) Trading Report - news.stocktradersdaily.com
BNP Paribas Financial Markets Acquires 39,599 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix at BioConnect: Strategic Advances in Wet AMD Treatment By Investing.com - Investing.com Canada
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust Corp - Defense World
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences - GlobeNewswire
Ocular Therapeutix CEO to Present at RBC, Mizuho, and Top Healthcare Conferences: Key Dates for Investors - Stock Titan
The Manufacturers Life Insurance Company Sells 2,399 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Transcript : Ocular Therapeutix, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Hsbc Holdings PLC Buys 5,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Tower Research Capital LLC TRC Has $76,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for OCUL - Defense World
William Blair Brokers Decrease Earnings Estimates for OCUL - Defense World
Analysts Offer Predictions for OCUL FY2026 Earnings - Defense World
Ocular Therapeutix at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com India
Bearish: Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue and EPS estimates - simplywall.st
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 6.5% on Analyst Downgrade - Defense World
Analyst Expectations For Ocular Therapeutix's Future - Benzinga
Ocular Therapeutix (OCUL) Maintained as Buy by Needham, Price Ta - GuruFocus
Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations - Yahoo
Ocular Therapeutix Advances in Retinal Treatment Trials - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix: Q1 Earnings Snapshot - MySA
Ocular Therapeutix sees cash runway into 2028 - TipRanks
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings - Benzinga
Ocular Therapeutix reports Q1 EPS (38c), consensus (28c) - TipRanks
Ocular Therapeutix Inc earnings missed by $0.09, revenue fell short of estimates - Investing.com Nigeria
OCUL's Financial Position: Cash Reserves Expected to Sustain Unt - GuruFocus
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) M - GuruFocus
Raymond James maintains strong buy on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Ocular Therapeutix™ Reports First Quarter 2025 Results and Busin - GuruFocus
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocular Therapeutix Inc Stock (OCUL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kaiser Peter | Chief Development Officer |
May 23 '25 |
Sale |
7.17 |
2,974 |
21,324 |
207,104 |
| Heier Jeffrey S. | Chief Scientific Officer |
May 23 '25 |
Sale |
7.18 |
3,024 |
21,712 |
262,974 |
| Dugel Pravin | See Remarks |
May 23 '25 |
Sale |
7.18 |
21,219 |
152,352 |
3,499,099 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):